Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
about
Local tumour hyperthermia as immunotherapy for metastatic cancer.Targeting Hsp90 in urothelial carcinomaHigh-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888Differential heat shock protein localization in chronic lymphocytic leukemiaGeldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.Impact of butyrate on PKM2 and HSP90β expression in human colon tissues of different transformation stages: a comparison of gene and protein data17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemiaFunctional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cellsBlockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumorsMicroRNA-223 is a novel negative regulator of HSP90B1 in CLL.Targeted treatment for chronic lymphocytic leukemia.HSP90 Inhibitor Geldanamycin as a Radiation Response Modificator in Human Blood CellsNovel targeted treatment strategies for refractory chronic lymphocytic leukaemia.Heat shock proteins: essential proteins for apoptosis regulation.Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma.The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation.Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells.Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C.Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.Analysis of HSP90 Expression Is Valuable in the Differential Diagnosis of Ocular Surface Squamous Lesions.Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity.
P2860
Q26823968-577107C0-840C-4BDB-8C53-F4C7A7C7A6BAQ27023406-98029939-8108-401C-8428-9C963DA72B1EQ28477348-9FEA60B9-923F-4A10-8290-0FCD78B165AEQ33694521-48ADF52B-AF6D-4DE2-91A3-AC23DECC6809Q33825349-C484D868-2C74-41D3-BDBB-D9437A4C999FQ33997214-DB3F0ED5-78DC-4A91-9742-718573307E1DQ34051123-3BBF3634-303C-4D85-99CB-1ABE50567430Q34158824-717997C4-BBA4-47D8-924A-80BA9F9CD5A8Q34349298-B0ABC32E-801F-4D42-91C8-072086CB9107Q34989395-B9C24001-D200-4065-B9F0-CE1FF46C38ACQ35064987-49045260-8D4C-4B08-9B0D-958108AF3901Q35496723-27F2D8DE-D372-4769-9DD5-19E94567350CQ35599741-2E8DA2E1-5A51-4536-AADF-E7B2509DF07DQ36358976-06482F59-31D3-4EE8-B6A2-7CE0B50155B2Q36612602-EBC3D60E-38BD-4738-BE0D-269C1A9FF58DQ37081794-8697BE45-FF2E-4030-B431-8D2B21CABF63Q37386084-E2017017-72C7-47CF-8D06-56F7F58151E8Q37424099-B751C934-B498-4DAF-A6A7-8DDBDD4505F0Q37459656-F5EF21C2-8515-48E4-ABE0-AE16D8406843Q37866334-7B15EA88-307C-456F-B041-236257174648Q37874926-4655163C-1767-4605-AF90-DCFCA1EBE391Q38989476-0AA862C9-0702-4321-B13E-D341E0E3C39EQ39246737-DF813114-6756-4BFF-9186-443C3EA3F524Q39397789-F7FB1B8A-2F0C-48DA-861D-45FB8F4456F3Q39586039-B697255A-8C8A-41C0-8C0D-40D4A8FDCBF4Q42222764-464A3D43-8F5B-4452-B1EA-C22FF196C97CQ54117138-8518F3DD-64F5-42B1-9720-A395A15B9F61Q55311618-6F3F69AF-E707-41C7-BF77-E260EB0D01F7
P2860
Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Hsp90 inhibition has opposing ...... c lymphocytic leukaemia cells.
@en
Hsp90 inhibition has opposing ...... c lymphocytic leukaemia cells.
@nl
type
label
Hsp90 inhibition has opposing ...... c lymphocytic leukaemia cells.
@en
Hsp90 inhibition has opposing ...... c lymphocytic leukaemia cells.
@nl
prefLabel
Hsp90 inhibition has opposing ...... c lymphocytic leukaemia cells.
@en
Hsp90 inhibition has opposing ...... c lymphocytic leukaemia cells.
@nl
P2093
P2860
P356
P1433
P1476
Hsp90 inhibition has opposing ...... c lymphocytic leukaemia cells.
@en
P2093
A R Pettitt
G G Johnson
N Rockliffe
P D Sherrington
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210893
P407
P577
2007-11-05T00:00:00Z